SHORT MINI-FUTURE - BIOGEN IDEC | Delayed Deutsche Boerse AG 08:22:05 17/05/2024 pm IST | ||
| 17.02 EUR | +0.95% |
|
| Current month | -8.07% | ||
| 1 month | -17.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 17.02 | +0.95% |
| 16/24/16 | 16.86 | +3.95% |
| 15/24/15 | 16.22 | -6.46% |
| 14/24/14 | 17.34 | -0.46% |
| 13/24/13 | 17.42 | -1.25% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 08:22 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VQ8QB0 |
| ISIN | DE000VQ8QB08 |
| Date issued | 16/06/2021 |
| Strike | 411.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.88 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.73 € |
|---|---|
| Lowest since issue | 1.94 € |
| Spread | 0.03 € |
| Spread % | 0.18% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
230
USD
Average target price
285.9
USD
Spread / Average Target
+24.29%
- Stock Market
- Certificates
- Certificat